Prevention and Management of Antineoplastic Extravasation Injury

Abstract

Goal

The goal of this program is to inform the participant of practical ways to prevent, identify, and manage the extravasation of anti-neoplastic agents.

Objectives

At the completion of this program the participant will be able to:

List antineoplastic agents known to be vesicants or irritants.

Identify the signs and symptoms of extravasation injury.

Recommend a procedure for the safe administration of vesicant medications.

Describe the appropriate management of antineoplastic-induced extravasation injury.

Keywords

adverse reaction antineoplastic agents chemotherapy extravasation intravenous administration vesicant

Get full access to this article

View all access options for this article.

References

Black

Vein extravasation: A severe complication of I.V. therapy. Parenterals. 1988; 2: 5–7.

Mateu

, Alzamora

, Fanco

Needlestick injuries and hazardous drugs. Am J Health Syst Pharm. 1996; 53: 1068, 1071.

Larson

D.L.

Treatment of tissue extravasation by antitumor agents. Cancer. 1982; 49: 1796–99.

Cox

, Stuart-Harris

, Abdini

The management of cytotoxic-drug extravasation: Guide-lines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust. 1988; 148: 185–89.

Dorr

R.T.

Antidotes to vesicant chemotherapy extravasations. Blood Rev. 1990; 4: 41–60.

Terry

, Baranowski

, Lonsway

R.A.

. eds. Intravenous Therapy: Clinical Principles and Practice. Philadelphia, PA: W.B. Saunders; 1995: 260–2, 422–3.

Boyle

D.M.

, Engelking

Vesicant extravasation: Myths and realities. Oncol Nurs Forum. 1995; 22: 57–67.

Fish

L.S.

The prevention and extravasation of antineoplastic agents. Hospital Pharmacy Hotline. 1990; 3: 1–3.

Parashos

P.J.

A rational approach for the management of tissue extravasation due to antineoplastic drugs. MicroLink Update. April 1986; 2: 13–5.

10.

Oncology Nursing Society Clinical Practice Committee. Cancer Chemotherapy Guidelines: Recommendations for the Management of Vesicant Extravasation, Hypersensitivity, and Anaphylaxis. Philadelphia, PA: Oncology Nursing Press; 1992.

11.

Rudolph

Larson DL. Etiology and treatment of chemotherapeutic agent extravasation injuries: A review. J Clin Oncol. 1987; 5: 1116–26.

12.

Ignoffo

R.J.

, Friedman

M.A.

Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev. 1980; 7: 17–27.

13.

Dorr

R.T.

Pharmacologic management of vesicant chemotherapy extravasation. In: Dorr

R.T.

, Von Hoff

D.D.

, eds. Cancer Chemotherapy Handbook. 2nd ed. Norwalk, CT: Appleton & Lange; 1994, 109–18.

14.

Wood

L.S.

, Gullo

S.M.

IV vesicants: How to avoid extravasation. Am J Nurs. 1993; 93: 42–6.

15.

Zenk

K.E.

Management of intravenous extravasations. Infusion. 1981; 5: 77–9.

16.

Lokich

J.J.

, Moore

Drug extravasation in cancer chemotherapy [letter]. Ann Intern Med. 1986; 104: 124.

17.

Moore

, Strong

, Childress

Surveillance of the patient receiving infusional cancer chemotherapy: Nursing role in recognition and management of catheter-related complications. J Infus Chemother. 1996; 6: 171–80.

18.

Banerjee

, Brotherston

T.M.

, Lamberty

B.G.H.

Cancer chemotherapy agent-induced perivenous extravasation injuries. Postgrad Med J. 1987; 63: 5–9.

19.

Lauvin

, Miglianico

, Hellegouarc

H.R.

Skin cancer occurring 10 years after the extravasation of doxorubicin. N Engl J Med. 1995; 332: 754.

20.

Bertelli

Prevention and management of extravasation of cytotoxic drugs. Drug Safety. 1995; 12: 245–55.

21.

Shenaq

S.M.

, Abbase

E.A.

, Friedman

J.D.

Soft-tissue reconstruction following extravasation of chemotherapeutic agents. Surg Oncol Clin N Am. 1996; 5: 825–45.

22.

Birdsall

, Naliboff

A.R.

How do you manage chemotherapy extravasation?

Am J Nurs. 1988; 88: 228–30.

23.

Smith

Prevention and treatment of extravasation. Br J Paren Ther. 1985; 6: 114–20.

24.

Holmes

B.C.

Administration of cancer chemotherapy agents. In: Dorr

R.T.

, Von Hoff

D.D.

, eds. Cancer Chemotherapy Handbook. 2nd ed. Norwalk, CT: Appleton & Lange; 1994, 57–94.

25.

Jameson

, O'Donnell

Guidelines for extravasation of intravenous drugs. Infusion. 1983; 7: 157–61, 165.

26.

Hirsh

J.D.

, Conlon

P.F.

Implementing guidelines for managing extravasation of antineoplastics. Am J Hosp Pharm. 1983; 40: 1516–19.

27.

Flemmer

, Chan

J.S.L.

A pediatric protocol for management of extravasation injuries. Pediatr Nurs. 1993; 19: 355–58, 424.

28.

Wolfe

C.A.

, Linkewich

J.A.

Preparation of guidelines for the avoidance and treatment of extravasation due to anti-neoplastic drugs. Hosp Pharm. 1987; 22: 125–31.

29.

Hankin

F.M.

, Louis

D.S.

Extravasation of chemotherapeutic agents. Am Fam Physician. 1985; 31: 147–50.

30.

Hessen

J.A.

Protocol for treatment of vesicant antineoplastic extravasation. Hosp Pharm. 1989; 24: 705–9.

31.

Dini

, Forno

, Gozza

Combined management in the treatment of epidoxorubicin extravasation. Support Care Cancer. 1995; 3: 150–2.

32.

Dorr

, Soble

M.J.

, Liddil

J.D.

Mitomycin-C skin toxicity studies in mice: Reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. J Clin Oncol. 1986; 4: 1399–1404.

33.

Bertelli

, Gozza

, Forno

G.B.

Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: A prospective clinical study. J Clin Oncol. 1995; 13: 2851–55.

34.

Olver

I.N.

, Aisner

, Hament

A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol. 1988; 6: 1732–5.

35.

Ludwig

C.U.

, Stoll

, Obrist

Prevention of cytotoxic drug induced skin ulcers with dimethyl sulfoxide (DMSO) and a-tocopherole. Eur J Cancer Clin Oncol. 1987; 23: 327–329.

36.

Lawrence

H.J.

, Goodnight

S.H.

Dimethyl sulfoxide and extravasation of anthracycline agents. Ann Intern Med. 1983; 98: 1025.

37.

Alberts

D.S.

, Dorr

R.T.

Case report: Topical DMSO for mitomycin-C induced skin ulceration. Oncol Nurs Forum. 1991; 18: 693–5.

38.

Lawrence

H.J.

, Walsh

, Zapotowski

K.A.

Topical dimethylsulfoxide may prevent tissue damage from anthracycline extravasation. Cancer Chemother Pharmacol. 1989; 23: 316–8.

39.

Larson

D.L.

What is the appropriate management of tissue extravasation by antitumor agents?

Plast Reconstr Surg. 1985; 75: 397–402.

40.

Olver

I.N.

, Schwarz

M.A.

Use of dimethyl sulfoxide in limiting tissue damage caused by extravasation of doxorubicin. Cancer Treat Rep. 1983; 67: 407–8.

41.

McEvoy

G.K.

, Litvak

, Welsh

O.H.

., eds. AHFS 99 Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 1999.

42.

Mosby's GenRx: The Complete Reference for Generic and Brand Drugs. St. Louis, MO: Mosby Inc.; 1999.

43.

DepoCyt (cytarabine liposome injection) package insert. San Diego, CA/Emeryville, CA: DepoTech Corporation/Chiron Therapeutics; April 1999.

44.

Dezube

B.J.

Safety assessment: Doxil (doxorubicin HCl liposome injection) in refractory AIDS-related Kaposi's sarcoma. Doxil Clinical Series. Menlo Park, CA: Sequus Pharmaceuticals; 1997, 1–7.

45.

Gabizon

A.A.

Liposomal anthracyclines. Hematol Oncol Clin North Am. 1994; 8: 431–50.

46.

Davis

M.E.

, DeSantis

, Klemm

A flow sheet for follow-up after chemotherapy extravasation. Oncol Nurs Forum. 1995; 22: 979–83.

47.

Amonafide. In: Dorr

, Von Hoff

eds. Cancer Chemotherapy Handbook. 2nd ed. Norwalk, CT: Appleton & Lange; 1994, 175–82.

48.

Echinomycin. In: Dorr

, Von Hoff

eds. Cancer Chemotherapy Handbook. 2nd ed. Norwalk, CT: Appleton & Lange; 1994, 416–9.

49.

Esorubicin. In: Dorr

, Von Hoff

eds. Cancer Chemotherapy Handbook. 2nd ed. Norwalk, CT: Appleton & Lange; 1994, 439–43.

50.

Piroxantrone. In: Dorr

, Von Hoff

eds. Cancer Chemotherapy Handbook. 2nd ed. Norwalk, CT: Appleton & Lange; 1994, 791–4.

51.

Kara

, Ross

Severe soft tissue necrosis after extravasation of mitox-antrone: Case report. Can J Plast Surg. 1998; 6: 204–6.

52.

Bailey

W.L.

, Crump

R.M.

Taxol extravasation: A case report. Can Oncol Nurs J. 1997; 7: 96–9.

53.

Bicher

, Levenback

, Burke

T.W.

Infusion site soft-tissue injury after paclitaxel administration. Cancer. 1995; 76: 116–20.

54.

Finley

R.S.

Administration of cancer chemotherapy. In: Finlay

R.S.

, Balmer

, eds. Concepts in Oncology Therapeutics. 2nd edition. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 1998, 173–95.

55.

Busulfex (busulfan) injection package insert. Minnetonka, MN: Orphan Medical; February 1999.

56.

Berg

Irinotecan hydrochloride: Drug profile and nursing implications of a topoisomerase I inhibitor in patients with advanced colorectal cancer. Oncol Nurs Forum. 1998; 25: 535–43.

57.

Valstar (valrubicin) sterile solution for intravesical instillation package insert. Bedford, OH/Rochester, NY: Ben Venue Laboratories/Medeva Pharmaceuticals, Inc.; June 1998.